Plus   Neg

Riding High: DBV Technologies


The American Depository Shares of France-based DBV Technologies SA (DBVT), which touched an all-time high of $48.11 last week, are up more than 36% year-to-date.

DBV Technologies is focused on developing safe, effective and patient-friendly therapy for food and pediatric allergy patients, for whom there are no currently approved treatments. The Company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using a novel technology platform called Viaskin.

The Company's most advanced product candidate is Viaskin Peanut, which is under a trial, dubbed PEPITES.

PEPITES is a pivotal phase III trial assessing the efficacy and safety of Viaskin Peanut 250 µg in approximately 330 pediatric patients in around 30 centers in North America (United States and Canada), Australia and Europe.

The topline results from PEPITES are expected this month.

Another phase III trial of Viaskin Peanut that is underway is known as REALISE.

REALISE is placebo-controlled phase III study designed to assess the use of Viaskin Peanut 250 µg in routine medical practice and generate safety data after six months of blinded treatment in patients four to 11 years of age. The results from the REALISE study are expected later this year.

A follow-up study to PEPITES, known as PEOPLE, is also ongoing. Enrolment in this study was completed in August of this year.

The other Viaskin product candidates are:

-- Viaskin Milk, under phase IIb trial, dubbed MILES, and a phase IIA investigator-initiated clinical trial, known as SMILEE and
-- Viaskin Egg, under pre-clinical testing.

Results from MILES and SMILEE are expected in the first half of 2018.

With an important clinical trial catalyst coming up this month for DBV Technologies, it's time to keep an eye on this stock.

DBVT has traded in a range of $31.87 to $48.11 over the last 1 year. The stock closed Friday's trading at $47.92, up 3.79%.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT